Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Akebia Therapeutics, Inc. (AKBA) had Revenue of $57.62M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$57.62M
Net Income	$-12.24M
Cost of Goods Sold	$12.54M
Gross Profit	$45.09M
Operating Expenses	$66.17M
Operating Income	$-8.55M
Non-Operating Income/Expense	$-2.68M
Pre-Tax Income	$-11.23M
Normalized Pre-Tax Income	$-11.23M
Income after Taxes	$-12.24M
Income from Continuous Operations	$-12.24M
Consolidated Net Income/Loss	$-12.24M
Normalized Income after Taxes	$-12.24M
EBIT	$-8.55M
EBITDA	$-8.23M
Weighted-Average Shares Outstanding (Basic)	257.16M
Weighted-Average Shares Outstanding (Diluted)	257.16M
Earnings per Share (EPS) (Basic)	$-0.05
Earnings per Share (EPS) (Diluted)	$-0.05
Balance Sheet Financials
Current Assets	$252.96M
Property, Plant, and Equipment	$1.22M
Long-Term Assets	$123.61M
Total Assets	$376.56M
Current Liabilities	$162.94M
Long-Term Debt	$48.25M
Long-Term Liabilities	$181.02M
Total Liabilities	$343.95M
Common Equity	$32.61M
Tangible Shareholders Equity	$-26.43M
Shareholders Equity	$32.61M
Common Shares Outstanding	265.43M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$67.99M
Cash Flow from Investing Activities	$-7.93M
Cash Flow from Financial Activities	$72.93M
Beginning Cash	$53.55M
End Cash	$186.54M
Increase/Decrease in Cash	$132.99M
Stock-Based Compensation	$11.28M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.55
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.60
Debt to Equity Ratio	1.48
Gross Margin	78.25%
Operating Margin	-14.84%
EBIT Margin	-14.84%
EBITDA Margin	--
Pre-Tax Profit Margin	-19.50%
Profit Margin	-21.25%
Free Cash Flow	$67.87M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.80
Receiveable Turnover	1.23
Days Sales in Receivables	73.46
Return on Equity	-37.55%
Return on Tangible Equity	46.32%
Return on Assets	-3.25%
Return on Investments	-15.14%
Book Value Per Share	$0.12
Free Cash Flow per Share	$0.26
Operating Cash Flow per Share	$0.26

Data from Zacks Investment Research, Inc.